MED
MEDIFAST INC
Next earnings Aug 3, 2026 · consensus $-0.66 EPS, $73.4M rev
Last earnings -2.6% on 2026-05-04
$10.51
▲ +3.04%$10.51▼ -21.04%
over 1Y
L $9.53EODHDH $15.22
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W-4.6%
1M-17.4%
3M+7.8%
YTD+1.1%
1Y-21.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Sell
Conservative balance sheet (liabilities/equity 0.25x); but revenue fell -36.0% YoY.
Revenue (FY2025) $386M · FY2025
MEDIFAST INC shows $386M in FY2025 revenue (-36.0% YoY), a -4.8% net margin, and -9.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.53B | $1.60B | $1.07B | $602M | $386M |
| Gross profit | $1.13B | $1.14B | $776M | $445M | $275M |
| Operating income | $216M | $185M | $126M | $2.88M | -$14.2M |
| Net income | $164M | $144M | $99.4M | $2.09M | -$18.7M |
| Diluted EPS | $13.89 | $12.73 | $9.10 | $0.19 | -$1.70 |
| Net margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$26.2M
EV / EBITDA904.0
EV / Sales0.1
EV / FCF21.0
P / FCF92.5
PEG (trailing)—
Earnings yield-16.2%
FCF yield1.1%
Quality & risk
ROIC (est.)-5.6%
Free cash flow$1.25M
Total debt$0.00
Net cash$89.3M
Altman Z-Score4.44 safe
Piotroski F-Score4/9
Capital returns
Buyback yield0.0%
Dividend yield (est.)0.2%
Shareholder yield0.2%
Shares Δ YoY+0.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-01
- 8-K Officer / director change2026-05-26
- 8-K Earnings results2026-05-04
- 10-Q Quarterly report2026-05-04
- DEF 14A Proxy statement2026-04-06
- 8-K Officer / director change2026-03-20
- 8-K Earnings results2026-02-17
- 10-K Annual report2026-02-17
- 8-K Officer / director change2026-01-05
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-292026-06-01open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗3Period ending 2026-05-192026-05-28open ↗3Period ending 2026-05-192026-05-28open ↗8-KPeriod ending 2026-05-192026-05-26open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗
Frequently asked
- Is MEDIFAST INC (MED) a buy?
- MED currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.25x); but revenue fell -36.0% YoY.
- What is MEDIFAST INC's quality score?
- MED scores 47.94117647058823/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000910329, latest 10-Q filed 2026-05-04) · EODHD · as of 6/26/2026, 6:45:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.